Nicole Onetto - Jun 9, 2022 Form 4 Insider Report for Viracta Therapeutics, Inc. (VIRX)

Role
Director
Signature
/s/ Daniel Chevallard, as Attorney-in-Fact
Stock symbol
VIRX
Transactions as of
Jun 9, 2022
Transactions value $
$0
Form type
4
Date filed
6/10/2022, 05:07 PM
Previous filing
Mar 28, 2022
Next filing
Jun 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIRX Stock Option (Right to Buy) Award $0 +40K $0.00 40K Jun 9, 2022 Common Stock 40K $3.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date.